[{"bbox": [90, 99, 367, 130], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [90, 164, 2241, 300], "category": "Table", "text": "<table><tr><td>Project in Progress:-</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TECHNOLOGY FEE Project TT 5- Part Diff. Hematology Analyzers</td><td>20.74</td><td>43.51</td><td></td><td>288.05</td><td>352.30</td></tr><tr><td>Total</td><td>20.74</td><td>43.51</td><td>-</td><td>288.05</td><td>352.30</td></tr></table>"}, {"bbox": [90, 335, 160, 361], "category": "Section-header", "text": "Notes"}, {"bbox": [90, 365, 2241, 430], "category": "List-item", "text": "1. *The Company does not have any capital work in progress/intangible asset under development whose completion is overdue or has exceeded its cost compared to original plan. The Company does not have any project which is temporary suspended."}, {"bbox": [90, 430, 875, 461], "category": "List-item", "text": "2. Management is verifying the assets physically on regular intervals."}, {"bbox": [90, 461, 2241, 525], "category": "List-item", "text": "3. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, V, I, II and III."}, {"bbox": [1144, 1487, 1188, 1514], "category": "Page-footer", "text": "218"}]